FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kringle Pharma FCF Yield % Related Terms
Kringle Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4884 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Kringle Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kringle Pharma (TSE:4884) has a FCF Yield % of -28.88 as of Jul. 01, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kringle Pharma and its competitors. According to the industry distribution chart, Kringle Pharma ranks #1050 out of 1414 companies in the Biotechnology industry, placing it in the top 74.3%.
Is Kringle Pharma's FCF Yield % too high?
Kringle Pharma's current FCF Yield % is -28.88. Based on the distribution chart, Kringle Pharma ranks #1050 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kringle Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kringle Pharma ranks #1050 out of 1414 companies for FCF Yield %. This places Kringle Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current FCF Yield % is -28.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円496.31, compared to a current price of 円324.00 — trading 34.7% below its estimated fair value. The current FCF Yield % is -28.88. Kringle Pharma's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current FCF Yield % is -28.88 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円324.00 is trading 34.7% below its estimated GF Value™ of 円496.31.
GuruFocus considers Kringle Pharma to be Possible Value Trap.
Key valuation signals for TSE:4884:
FCF Yield %: -28.88
GF Value™: 円496.31 vs. price of 円324.00 (34.7% below fair value)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
45GF Score
Get the complete analysis for TSE:4884
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
